UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Accelerated Titration Designs for Phase I Clinical Trials in Oncology

JNCI : Journal of the National Cancer Institute, 1997-08, Vol.89 (15), p.1138-1147

1997

Volltextzugriff (PDF)

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms

Journal of clinical oncology, 1998-09, Vol.16 (9), p.2986-2999

1998

Volltextzugriff (PDF)

Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?

Journal of clinical oncology, 2001-01, Vol.19 (1), p.265-272

2001

Volltextzugriff (PDF)

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Journal of clinical oncology, 2001-04, Vol.19 (8), p.2319-2333

2001

Volltextzugriff (PDF)

Clinical toxicities encountered with paclitaxel (TAXOL®)

Seminars in oncology, 1993-08, Vol.20 (4), p.1-15

1993

Volltextzugriff (PDF)

Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer

Annals of oncology, 2001-08, Vol.12 (8), p.1067-1073

2001

Volltextzugriff (PDF)

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

JNCI : Journal of the National Cancer Institute, 2000-02, Vol.92 (3), p.205-216

2000

Volltextzugriff (PDF)

Fluorouracil Modulation in Colorectal Cancer: Lack of Improvement With N -Phosphonoacetyl- l -Aspartic Acid or Oral Leucovorin or Interferon, But Enhanced Therapeutic Index With Weekly 24-Hour Infusion Schedule—An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study

Journal of clinical oncology, 2001-05, Vol.19 (9), p.2413-2421

2001

Volltextzugriff (PDF)

Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996

Annals of oncology, 1996-08, Vol.7 (6), p.567

Arbuck, S G

1996

Volltextzugriff (PDF)

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103

Journal of clinical oncology, 1993-12, Vol.11 (12), p.2405-2410

1993

Volltextzugriff (PDF)

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial

Journal of clinical oncology, 1991-12, Vol.9 (12), p.2128-2133

1991

Volltextzugriff (PDF)

Biochemical Correlates of mTOR Inhibition by the Rapamycin Ester CCI-779 and Tumor Growth Inhibition

Clinical cancer research, 2001-06, Vol.7 (6), p.1758-1764

2001

Volltextzugriff (PDF)

Clinical pharmacology of UCN-01 : initial observations and comparison to preclinical models

Cancer chemotherapy and pharmacology, 1998-08, Vol.42 (S1), p.S54-S59

1998

Volltextzugriff (PDF)

Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial

Journal of clinical oncology, 1995-08, Vol.13 (8), p.2056-2065

1995

Volltextzugriff (PDF)

Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients

Journal of clinical oncology, 1997-04, Vol.15 (4), p.1492-1501

1997

Volltextzugriff (PDF)

Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma

Journal of clinical oncology, 1997-08, Vol.15 (8), p.2905-2909

1997

Volltextzugriff (PDF)

Current dosage and schedule issues in the development of paclitaxel (TAXOL®)

Seminars in oncology, 1993-08, Vol.20 (4), p.31-39

1993

Volltextzugriff (PDF)

An overview of topoisomerase I-targeting agents

Seminars in hematology, 1998-07, Vol.35 (3 Suppl 4), p.3

1998

Volltextzugriff (PDF)

Paclitaxel: what schedule? What dose?

Journal of clinical oncology, 1994-02, Vol.12 (2), p.233-236

Arbuck, S G

1994

Volltextzugriff (PDF)

Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma

Journal of clinical oncology, 1993-09, Vol.11 (9), p.1737-1745

1993

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma

Journal of clinical oncology, 1994-03, Vol.12 (3), p.560-568

1994

Volltextzugriff (PDF)

Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute

Seminars in oncology, 1997-04, Vol.24 (2), p.219-240

1997

Volltextzugriff (PDF)

Relation of systemic exposure to unbound etoposide and hematologic toxicity

Clinical pharmacology and therapeutics, 1991-10, Vol.50 (4), p.385-393

1991

Volltextzugriff (PDF)

Paclitaxel: current developmental approaches of the National Cancer Institute

Seminars in oncology, 1995-12, Vol.22 (6 Suppl 15), p.55-63

Arbuck, S G

1995

Volltextzugriff (PDF)

Cyclin-Dependent Kinases: Initial Approaches to Exploit a Novel Therapeutic Target

Pharmacology & therapeutics (Oxford), 1999-05, Vol.82 (2), p.285-292

1999

Volltextzugriff (PDF)

1 – 25 von 118

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(108)
Mit Volltextzugriff
(77)

Publikationsform

Sprache

Englisch
(118)

Erscheinungsjahr

n.n

Thema

Humans
(96)
Science & Technology
(69)
Life Sciences & Biomedicine
(68)
Female
(56)
Oncology
(56)
Biological And Medical Sciences
(55)
Medical Sciences
(54)
Pharmacology. Drug Treatments
(51)
Antineoplastic Agents
(49)
Middle Aged
(40)
Adult
(39)
Chemotherapy
(39)
Male
(38)
Aged
(37)
Neoplasms - Drug Therapy
(35)
Clinical Trials As Topic
(22)
Antineoplastic Agents - Therapeutic Use
(21)
Drug Administration Schedule
(21)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(18)
Infusions, Intravenous
(17)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Accelerated Titration Designs for Phase I Clinical Trials in Oncology

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms

Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Clinical toxicities encountered with paclitaxel (TAXOL®)

Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Fluorouracil Modulation in Colorectal Cancer: Lack of Improvement With N -Phosphonoacetyl- l -Aspartic Acid or Oral Leucovorin or Interferon, But Enhanced Therapeutic Index With Weekly 24-Hour Infusion Schedule—An Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study

Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103

Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial

Biochemical Correlates of mTOR Inhibition by the Rapamycin Ester CCI-779 and Tumor Growth Inhibition

Clinical pharmacology of UCN-01 : initial observations and comparison to preclinical models

Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial

Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients

Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma

Current dosage and schedule issues in the development of paclitaxel (TAXOL®)

An overview of topoisomerase I-targeting agents

Paclitaxel: what schedule? What dose?

Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma

Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma

Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute

Relation of systemic exposure to unbound etoposide and hematologic toxicity

Paclitaxel: current developmental approaches of the National Cancer Institute

Cyclin-Dependent Kinases: Initial Approaches to Exploit a Novel Therapeutic Target

Suchergebnisse filtern